Published in Clinical Oncology Week, February 19th, 2007
"Our excellent Phase I/II results show Davanat, when co-administered with 5-FU, stabilized the disease and improved the quality of life for many of the end-stage cancer patients," said David Platt, PhD, president and chief executive officer, Pro-Pharmaceuticals, Inc. "When we combine the very positive results from those trials, with the data expected...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Oncology Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.